Drug Safety Update: recombinant human erythropoietins

9 January 2018

The January 2018 issue of Drug Safety Update is now online and contains an article about a very rare risk of severe cutaneous adverse reactions with recombinant human erythropoietins. Since these medicines are sometimes used in the treatment of anaemia in premature babies, we thought the advice might be of interest to our members.

For further information, visit the website.